Safe, Effective,
Biological Medicines
International Laboratory
Standard
Breakthrough Medical
Treatments
CAR T-cells for Multiple Myeloma
CAR T-cells for Acute
Lymphoblastic Leukemia.
Non Hodgkin Lymphoma
Swiss Laboratories
One lab is 2000 Sq. Meters and specializes in advanced genetics and cell therapy for cancer. This lab produces highly advanced cellular products for the treatment of Hematological Cancers such as: Multiple Myeloma, Leukemia and Lymphoma.
Our second Lab is 330 Sq. Meters which specializes in the production of stem cells for the treatment of chronic disease. Our Labs are maintained and certified at an international standard
Treatment Of The COVID-19 Pneumonia With MSC Stem Cells
![bird](/media/treatment-of-the-covid-19-pneumonia-with-msc-stem-cells.png)
Treatment Period March 12th To March 21th
“Two common and one severe patient were significantly improved in 2 days after MSC transplantation. Among them, two common and one severe Patient were recovered and discharged in 10 days after treatment. After treatment the peripheral lymphocytes were increased, the C-reactive protein decreased, and the overactivated cytokine-secreting immune cells CXCR3+CD11c+T cells, CXCR3+CD8+T cells, and CXCR3+NK cells dissapeared in 3-6 days. In addition, a group of CD14+CD11c+CD11b mid regulatory DC cell population dramatically increased. Meanwhile the level of TNF-@ was significantly decreased, while IL-10 increased in MSC treatment group compared to the placebo control group. Furthermore, the gene expression profile showed MSC were ACE2 and TMPRSS2 which indicated MSC’s are free from COVID19 infection. Thus, the intravenous transplantation of MSC’s was safe and effective for treatment in patients with COVID-19 pneumonia, especially for the Patients in critically severe conditions.”
OUR TREATMENTS
Swiss Breakthrough Treatments for Chronic Disease